Trial Profile

Phase II Study of Everolimus Beyond Progression in Postmenopausal Women With Advanced, Hormone Receptor Positive Breast Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 06 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Anastrozole; Fulvestrant; Fulvestrant; Letrozole; Megestrol; Tamoxifen
Indications Breast cancer
Focus Therapeutic Use

Most Recent Events

06 Jan 2022 Status changed from active, no longer recruiting to discontinued.
24 Jan 2021 Planned primary completion date changed from 1 Nov 2020 to 1 Nov 2021.
06 Nov 2019 Planned End Date changed from 1 Oct 2020 to 1 Nov 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com